MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
复制标题
DOI：
10.1586/erv.10.111
复制
发表时间：
2010-10-01
影响因子：
6.2
通讯作者：
El Sahly, Hana
中科院分区：
文献类型：
--
作者：
El Sahly, Hana
从明矾盐作为疫苗佐剂的许可到MF 59（TM）的许可大约经过了70年。MF 59是一种水包油型乳剂，目前已获准用于老年人季节性流感疫苗的佐剂。其作用机制尚未完全了解，但似乎涉及抗原和树突细胞之间相互作用的增强。当与季节性流感疫苗一起使用时，针对某些但不是全部季节性疫苗流感毒株的血凝抑制抗体滴度会增加。当MF 59与新的流感抗原如H9和H5组合时，佐剂作用更明显。佐剂的使用与局部和全身性疫苗接种后早期不良事件（3-7天）的频率增加相关，但此后未观察到不良事件增加。目前，MF 59作为佐剂与其他抗原如大流行性流感抗原和巨细胞病毒抗原一起进行评估。
Approximately 70 years passed between the licensing of alum salts as vaccine adjuvants and that of MF59 (TM). MF59, an oil-in-water emulsion, is currently licensed for use in the elderly as an adjuvant in seasonal influenza vaccines. Its mechanism of action is not fully understood, but enhancement of the interaction between the antigen and the dendritic cell seems to be involved. When used with seasonal influenza vaccines, an increase occurs in the hemagglutination inhibition antibody titers against some, but not all, seasonal vaccine influenza strains. The adjuvant effect is more pronounced when MF59 is combined with novel influenza antigens such as H9 and H5. The use of the adjuvant is associated with an increase in the frequency of local and systemic early post-vaccine adverse events (3-7 days), but no increase in adverse events was observed thereafter. Currently, MF59 is under evaluation as an adjuvant with other antigens such as pandemic influenza antigens and cytomegalovirus antigens.